AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19967563 — intervention group
Group type: COMPARATOR
Intervention: Placebo (900 mg per day for 6 months)
Number of subjects: 25
Study 17872903 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF
Number of subjects: 41
Study 17872903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 16109326 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 48 mg/min
Number of subjects: 30
Study 16109326 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (VITC) 18 mg/min
Number of subjects: 30
Study 12601621 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (10 kg)
Number of subjects: 22
Study 12601621 — intervention group
Group type: COMPARATOR
Intervention: Control weight maintenance
Number of subjects: 22
Study 11082219 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ligation of the inferior thyroid artery (ITA)
Number of subjects: 48
Study 11082219 — intervention group
Group type: COMPARATOR
Intervention: No ligation of the inferior thyroid artery (ITA)
Number of subjects: 48
Study 8875514 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented total parenteral nutrition (GTPN) with 25 g crystalline L-glutamine per 24 h
Number of subjects: 38
Study 8875514 — intervention group
Group type: COMPARATOR
Intervention: Conventional total parenteral nutrition (CTPN)
Number of subjects: 38
Study 1520230 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirective psychotherapy
Number of subjects: 0
Study 1520230 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour therapy
Number of subjects: 0
Study 1520230 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 0
Study 1520230 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation/placebo
Number of subjects: 0
Study 6354663 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times daily)
Number of subjects: 66
Study 6354663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 30705390 — intervention group
Group type: EXPERIMENTAL
Intervention: Support intervention (physicians endorsing, offering, and facilitating a referral to a weight loss programme)
Number of subjects: 1882
Study 30705390 — intervention group
Group type: COMPARATOR
Intervention: Advice (recommending weight loss)
Number of subjects: 1882
Study 30705390 — intervention group
Group type: EXPERIMENTAL
Intervention: Support intervention
Number of subjects: 1882
Study 28193288 — intervention group
Group type: EXPERIMENTAL
Intervention: Accreditation in 2016
Number of subjects: 2211
Study 28193288 — intervention group
Group type: COMPARATOR
Intervention: Accreditation in 2018
Number of subjects: 2211
Study 27358413 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages (SSBs) >5 servings/week
Number of subjects: 1868
Study 27358413 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificially sweetened beverages >5 servings/week
Number of subjects: 1868
Study 27358413 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural fruit juices >5 servings/week
Number of subjects: 1868
Study 27358413 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottled fruit juices >5 servings/week
Number of subjects: 1868
Study 27358413 — intervention group
Group type: COMPARATOR
Intervention: Sugar-sweetened beverages (SSBs) 1-5 servings/week
Number of subjects: 1868
Study 27358413 — intervention group
Group type: COMPARATOR
Intervention: Artificially sweetened beverages 1-5 servings/week
Number of subjects: 1868
Study 25084699 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural sanitation intervention under the Total Sanitation Campaign
Number of subjects: 100
Study 22036910 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg/day
Number of subjects: 1085
Study 22036910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1085
Study 18922689 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy assisted distal gastrectomy (LADG)
Number of subjects: 951
Study 18922689 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 951
Study 17197028 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 40
Study 17197028 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 40
Study 15860533 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental cycling exercise
Number of subjects: 18
Study 15860533 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant cycling exercise
Number of subjects: 18
Study 15860533 — intervention group
Group type: EXPERIMENTAL
Intervention: One-legged knee-extensor exercise
Number of subjects: 18
Study 11988191 — intervention group
Group type: EXPERIMENTAL
Intervention: Access AccuTnI assay (cTnI)
Number of subjects: 1763
Study 11988191 — intervention group
Group type: EXPERIMENTAL
Intervention: AxSym assay (cTnI)
Number of subjects: 1763
Study 11988191 — intervention group
Group type: EXPERIMENTAL
Intervention: Elecsys 3rd generation assay (cTnI)
Number of subjects: 1763
Study 11988191 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment
Number of subjects: 1763
Study 11988191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonelevated cTroponin levels
Number of subjects: 1763
Study 9921986 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial biopsy with isolated high grade prostatic intraepithelial neoplasia (PIN)
Number of subjects: 1824
Study 9921986 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial biopsy with borderline lesions
Number of subjects: 1824
Study 9921986 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prostate carcinoma detection
Number of subjects: 1824
Study 7551939 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin, ifosfamide and cisplatin (MIC) with radical radiotherapy
Number of subjects: 317
Study 7551939 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin, ifosfamide and cisplatin (MIC) with palliative care
Number of subjects: 317
Study 7551939 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin, ifosfamide and cisplatin (MIC)
Number of subjects: 317
Study 1720487 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 549
Study 1720487 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 549
Study 7137834 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal lavage for 72 hours
Number of subjects: 87
Study 7137834 — intervention group
Group type: COMPARATOR
Intervention: No lavage
Number of subjects: 87
Study 30807583 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincter Control Training (SCT) with masturbation aid device (Flip Zero)
Number of subjects: 35
Study 30807583 — intervention group
Group type: COMPARATOR
Intervention: Sphincter Control Training (SCT) without masturbation aid device
Number of subjects: 35
Study 28296722 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized addition PALs
Number of subjects: 211
Study 28296722 — intervention group
Group type: COMPARATOR
Intervention: +2.00 addition PALs
Number of subjects: 211
Study 28296722 — intervention group
Group type: COMPARATOR
Intervention: Single vision lenses (SVLs)
Number of subjects: 211
Study 26675247 — intervention group
Group type: EXPERIMENTAL
Intervention: Craigslist (CL)
Number of subjects: 134
Study 26675247 — intervention group
Group type: COMPARATOR
Intervention: Print Newspapers (PN)
Number of subjects: 134
Study 23354927 — intervention group
Group type: EXPERIMENTAL
Intervention: LAGB (gastric banding)
Number of subjects: 24
Study 23354927 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet
Number of subjects: 24
Study 22022472 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% protein diet
Number of subjects: 22
Study 22022472 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% protein diet
Number of subjects: 22
Study 22022472 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% protein diet
Number of subjects: 22
Study 22022472 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% protein breakfast
Number of subjects: 22
Study 18419878 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide DPI-B 360 microg twice-daily (total daily dose 720 microg)
Number of subjects: 1137
Study 18419878 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide DPI-A 400 microg twice-daily (total daily dose 800 microg)
Number of subjects: 1137
Study 18419878 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide DPI-B 180 microg once daily (total daily dose 180 microg)
Number of subjects: 1137
Study 18419878 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide DPI-A 200 microg once daily (total daily dose 200 microg)
Number of subjects: 1137
Study 18419878 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide DPI-B 360 microg twice-daily
Number of subjects: 1137
Study 18419878 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide DPI-A 400 microg twice-daily
Number of subjects: 1137
Study 18419878 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide DPI-B 180 microg once daily
Number of subjects: 1137
Study 18419878 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide DPI-A 200 microg once daily
Number of subjects: 1137
Study 18419878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1137
Study 16965691 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition with alanyl-glutamine dipeptide
Number of subjects: 72
Study 12856155 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg recombinant human TSH (rhTSH) followed by 2 mCi (74 MBq) iodine-131
Number of subjects: 9
Study 12856155 — intervention group
Group type: COMPARATOR
Intervention: 2 mCi (74 MBq) iodine-131 administered after stopping thyroid hormones to become hypothyroid
Number of subjects: 9
Study 11028139 — intervention group
Group type: EXPERIMENTAL
Intervention: Home rehabilitation
Number of subjects: 1487
Study 9368461 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentored teens
Number of subjects: 110
Study 9368461 — intervention group
Group type: COMPARATOR
Intervention: Control teens
Number of subjects: 110
Study 1328365 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment based upon weight reduction and sodium restriction
Number of subjects: 64
Study 1328365 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment using a stepped-care approach with atenolol as first choice drug
Number of subjects: 64
Study 3870293 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclatonium napadisilate (TM-723) at a dose of 50 mg
Number of subjects: 3
Study 3870293 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandine F2 alpha (PGF2 alpha) at a dose of 2 mg
Number of subjects: 3
Study 3870293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 30291013 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide (30-50 mg, subcutaneous injection once a week)
Number of subjects: 9463
Study 30291013 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched volume, subcutaneous injection once a week)
Number of subjects: 9463
Study 30291013 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide
Number of subjects: 9463
Study 30291013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9463
Study 27692424 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented corticotomy (experimental group, n = 15)
Number of subjects: 30
Study 27692424 — intervention group
Group type: COMPARATOR
Intervention: Control group (without augmented corticotomy, n = 15)
Number of subjects: 30
Study 24607553 — intervention group
Group type: EXPERIMENTAL
Intervention: etanercept (0.4 mg/kg twice weekly × 4 weeks)
Number of subjects: 34
Study 24607553 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study 24607553 — intervention group
Group type: EXPERIMENTAL
Intervention: etanercept
Number of subjects: 34
Study 23192918 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated IN.PACT Pacific balloons
Number of subjects: 85
Study 20206356 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone for 40 days
Number of subjects: 40
Study 20206356 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-treated patients)
Number of subjects: 40
Study 18380933 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 105
Study 18380933 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 105
Study 18380933 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin plus Levofloxacin
Number of subjects: 105
Study 18380933 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 105
Study 18596318 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (OO) based lipid emulsion
Number of subjects: 38
Study 18596318 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (SO) based lipid emulsion
Number of subjects: 38
Study 15028067 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (NSVT)
Number of subjects: 923
Study 15028067 — intervention group
Group type: COMPARATOR
Intervention: No nonsustained ventricular tachycardia (NSVT)
Number of subjects: 923
Study 15028067 — intervention group
Group type: EXPERIMENTAL
Intervention: NSVT index peaks < or =3 days prior to sustained VT/VF
Number of subjects: 923
Study 15028067 — intervention group
Group type: EXPERIMENTAL
Intervention: NSVT index peaks >3 days prior to sustained VT/VF
Number of subjects: 923
Study 11735351 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 27
Study 11735351 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 27
Study 11735351 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study 9431859 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg irbesartan once a day
Number of subjects: 215
Study 9431859 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg irbesartan once a day
Number of subjects: 215
Study 9431859 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg irbesartan twice a day
Number of subjects: 215
Study 9431859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 8237833 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 228
Study 8237833 — intervention group
Group type: COMPARATOR
Intervention: Conventional antiarrhythmic therapy
Number of subjects: 228
Study 3800090 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% povidone-iodine (Betadine)
Number of subjects: 395
Study 3800090 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline without scrubbing)
Number of subjects: 395
Study 30371101 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling-based narrative intervention
Number of subjects: 67
Study 30371101 — intervention group
Group type: COMPARATOR
Intervention: Didactic education (Control)
Number of subjects: 67
Study 29916140 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 11015
Study 29916140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11015
Study 29916140 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (PROSPER trial)
Number of subjects: 11015
Study 29916140 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (WOSCOPS trial)
Number of subjects: 11015
Study 27577515 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kVp tube voltage, low-concentration contrast media, iterative reconstruction (Group B)
Number of subjects: 154
Study 27577515 — intervention group
Group type: COMPARATOR
Intervention: 120 kVp tube voltage, high-concentration contrast media, filtered back projection reconstruction (Group A)
Number of subjects: 154
Study 25277022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued (lower workload)
Number of subjects: 92
Study 25277022 — intervention group
Group type: COMPARATOR
Intervention: Uncued (higher workload)
Number of subjects: 92
Study 25277022 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-frequency alpha (8 to 10.9 Hz)
Number of subjects: 92
Study 25277022 — intervention group
Group type: EXPERIMENTAL
Intervention: Task Load Index (TLI)
Number of subjects: 92
Study 25277022 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal theta and Engagement Index (El)
Number of subjects: 92
Study 22134839 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam (3.75 g/day)
Number of subjects: 60
Study 22134839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20638059 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (aromatase inhibitor)
Number of subjects: 36
Study 20638059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17999256 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic drugs (various types)
Number of subjects: 1460
Study 17999256 — intervention group
Group type: COMPARATOR
Intervention: Psychiatrists' management practices
Number of subjects: 1460
Study 16330296 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrozit (test formulation)
Number of subjects: 28
Study 16330296 — intervention group
Group type: COMPARATOR
Intervention: Azitrocin (reference formulation)
Number of subjects: 28
Study 12480477 — intervention group
Group type: EXPERIMENTAL
Intervention: Early learning phase using simple categorization rules
Number of subjects: 0
Study 12480477 — intervention group
Group type: EXPERIMENTAL
Intervention: Later learning phase using similarity-based exemplar retrieval
Number of subjects: 0
Study 9472885 — intervention group
Group type: EXPERIMENTAL
Intervention: rtPA
Number of subjects: 12
Study 9472885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8600739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral graft harvest
Number of subjects: 65
Study 8600739 — intervention group
Group type: COMPARATOR
Intervention: Contralateral graft harvest
Number of subjects: 65
Study 8600739 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft harvest in knees with ACL reconstruction
Number of subjects: 65
Study 8600739 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor site morbidity
Number of subjects: 65
Study 2573234 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine plus neuroleptics (n = 82)
Number of subjects: 162
Study 2573234 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus neuroleptics (n = 80)
Number of subjects: 162
Study 4853932 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy with pyloroplasty (PGVP)
Number of subjects: 78
Study 4853932 — intervention group
Group type: COMPARATOR
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 78
Study 31571445 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg once daily for 12 weeks
Number of subjects: 76
Study 31571445 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg once daily for 12 weeks
Number of subjects: 76
Study 28255099 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP levels in individuals with newly detected AF (n=96)
Number of subjects: 7173
Study 28255099 — intervention group
Group type: COMPARATOR
Intervention: NT‐proBNP levels in individuals without AF (n=742)
Number of subjects: 7173
Study 28255099 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP cut-off of ≥125 ng/L
Number of subjects: 7173
Study 26340887 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue strengthening exercises at 60% of maximal tongue strength
Number of subjects: 51
Study 26340887 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue strengthening exercises at 80% of maximal tongue strength
Number of subjects: 51
Study 26340887 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue strengthening exercises at 100% of maximal tongue strength
Number of subjects: 51
Study 21709132 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care providers' written prescriptions for physical activity with additional physical activity resources
Number of subjects: 0
Study 21709132 — intervention group
Group type: COMPARATOR
Intervention: Health care providers' written prescriptions for physical activity without additional physical activity resources
Number of subjects: 0
Study 21420278 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made splint
Number of subjects: 56
Study 21420278 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated splint
Number of subjects: 56
Study 21420278 — intervention group
Group type: EXPERIMENTAL
Intervention: Both splints
Number of subjects: 56
Study 19454185 — intervention group
Group type: EXPERIMENTAL
Intervention: Graves' disease (hyperthyroidism)
Number of subjects: 78
Study 19454185 — intervention group
Group type: EXPERIMENTAL
Intervention: Hashimoto's thyroiditis (subclinical hypothyroidism)
Number of subjects: 78
Study 19454185 — intervention group
Group type: COMPARATOR
Intervention: Nodular goiter (control)
Number of subjects: 78
Study 19454185 — intervention group
Group type: COMPARATOR
Intervention: Hashimoto's thyroiditis (euthyroid)
Number of subjects: 78
Study 17826373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 958
Study 17826373 — intervention group
Group type: COMPARATOR
Intervention: Primary Percutaneous Coronary Intervention (PCI)
Number of subjects: 958
Study 15063430 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 2027
Study 15063430 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 2027
Study 15063430 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 2027
Study 15063430 — intervention group
Group type: EXPERIMENTAL
Intervention: First drug or combination
Number of subjects: 2027
Study 14962527 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 434
Study 14962527 — intervention group
Group type: COMPARATOR
Intervention: Best treatment without hormones (non-HRT)
Number of subjects: 434
Study 11174240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (tPA)
Number of subjects: 0
Study 9247941 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam with fentanyl
Number of subjects: 0
Study 9247941 — intervention group
Group type: COMPARATOR
Intervention: Midazolam without fentanyl
Number of subjects: 0
Study 9247941 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (general)
Number of subjects: 0
Study 8391063 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin A (retinol palmitate, orally 300,000 IU daily for 12 months)
Number of subjects: 307